Abstract： Objective： To observe the clinical effect of Compound Kushen Injection combined with Osimertinib Mesylate Tablets for epidermal growth factor receptor (EGFR) gene mutation in advanced nonsmall cell lung cancer (NSCLC) with phlegm- damp toxin accumulation syndrome. Methods： The clinical data of 80 patients with EGFR gene mutation in advanced NSCLC of phlegm-damp toxin accumulation type were given retrospective analysis. According to different treatment methods，the patients were divided into the observation group and the control group， with 40 cases in each group. The observation group was treated with Compound Kushen Injection combined with Osimertinib Mesylate Tablets， and the control group was simply treated with Osimertinib Mesylate Tablets. Both groups were treated for two courses， with 6 weeks being one course. The Karnofsky Performance Scale (KPS) scores were evaluated before and after treatment. The clinical effects and incidence of adverse reactions were compared between the two groups. Results：After treatment，the disease control rate in the observation group was higher than that in the control group (P＜0.05)； there was no significant difference in the objective remission rates and incidences of adverse reactions between the two groups (P＞0.05). The KPS score in the observation group was higher than that before treatment (P＜0.05)；the KPS score in the control group was higher than that before treatment， but the difference was not significant (P＞0.05). The KPS score in the observation group was higher than that in the control group (P＜0.05). Conclusion： The application of Compound Kushen Injection combined with Osimertinib Mesylate Tablets in the treatment of advanced NSCLC patients with EGFR gene mutation of phlegm- damp toxin accumulation type can improve the curative effects， reduce the incidence of adverse reactions， and have a significant improvement effect on the patient's health status.